According to the "Guideline for Diagnosis and Treatment of
Asthma" established by the Japanese Society of
Allergy in 1998, inhaled
adrenergic beta 2 agonists and inhaled
corticosteroids are recommended for treatment of
asthma. Thereafter, the development of new drugs for the treatment of
asthma has begun changing. The concepts upon which the development of
investigational drugs for
asthma are based include improvements of drug delivery systems (ease of use, long-acting preparations, fewer side-effects), device design and appropriate auxiliary instrumentation. Moreover, chronic
asthma has come to be recognized as an inflammatory disease of airway mucosa. At present, various
antiallergic compounds such as
tachykinin, leucotrien, PAF antagonists and others are under investigation thanks to the identification of new chemical mediators of airway
inflammation and studies have progressed to the synthesis and manufacturing of new
pharmaceuticals with antagonistic action. Thus, this review classified and introduced various new investigational anti-
asthma and further describes the structure-activity relationships of beta 2 agonists and inhaled
corticosteroids.